Alembic Pharmaceuticals Ltd. has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA)

Alembic Pharmaceuticals Ltd. has received final approval from the U.S. Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for a generic version of Triamcinolone Acetonide Injectable Suspension USP, at a concentration of 40 mg/mL. This regulatory milestone allows Alembic to commercially launch a key corticosteroid formulation into the U.S. generics market. Triamcinolone Acetonide is an established corticosteroid indicated for reducing inflammation, addressing symptoms such as redness, itching, and swelling across various skin and allergic conditions. The approved generic product is equivalent to the Reference Listed Drug and is positioned to meet demand for treatments requiring joint-injection and intralesional administration of triamcinolone. This approval bolsters Alembic's U.S. portfolio, bringing its total number of USFDA ANDA approvals to 227 (206 final, 21 tentative). The successful commercialization of this product is expected to contribute positively to the company's U.S. generics business growth in the coming quarters, supporting the strategic objective of expanding market share in regulated markets.